Development of VLP vaccine for RSV
Development of VLP vaccine for RSV
批准号:
9897525
负责人:
JORGE C BLANCO
金额:
$100.0万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-02-15 至 2022-02-28
关键词:
AcuteAgeAnimalsAntibodiesAntibody ResponseAntibody titer measurementBaculovirusesCell LineChildClinical TrialsComplicationCotton RatsDataDeveloping CountriesDevelopmentDiseaseDoseDropsEffectivenessFDA approvedFamily memberFetusGTP-Binding ProteinsGoalsHospitalizationHumanImmune responseImmune systemImmunityImmunizationImmunizeInfantInfectionLifeLungMaternal antibodyMeasuresMethodsMothersPathologyPhasePlacentaPlasmidsPopulationPregnancyProcessProductionProteinsProtocols documentationPublishingRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesRespiratory Tract InfectionsRespiratory syncytial virusRoleSafetySmall Business Technology Transfer ResearchTestingTimeTransfectionVaccinatedVaccinationVaccine Clinical TrialVaccine ProductionVaccinesVirusVirus-like particleVulnerable Populationscost effectiveexperiencehuman modelhuman pathogenimprovedin uterolarge scale productionmaternal vaccinationmortalityneonatal infectionneonateneutralizing antibodynovelnovel virusoffspringpreclinical developmentpregnantprotective effectprotocol developmentpuprespiratoryresponsesexvaccine candidatevaccine efficacyvaccine safetyvectorviral transmissionvirus development
中文摘要
呼吸道合胞病毒(RSV)是一种严重的人类病原体
英文摘要
Respiratory syncytial virus (RSV) is a significant human pathogen severely
impacting neonates and young children, but no vaccine exists to protect this vulnerable
population. Furthermore, direct vaccination of neonates is likely ineffective due to the
immaturity of their immune system, and neonate immunization is potentially unsafe. The
current view is that maternal vaccination is the best and safest approach to protection of
neonates through the passive transfer of maternal neutralizing antibodies in utero to the
fetus after maternal immunization. However, a complicating issue is that most people
have experienced RSV infections during their lifetimes. Thus, any maternal vaccine
must induce high levels of protective antibodies in the presence of pre-existing, but very
poorly neutralizing, anti-RSV antibodies.
In our STTR phase IIa project, we tested our novel RSV VLP vaccine candidates
in pregnant cotton rats, a surrogate human model, to determine the effect of prior RSV
exposure on induction of protective immune responses in these animals and to assess
maternal antibody transfer, protection, and safety in offspring of the immunized dams.
Our results showed that a single VLP immunization of RSV primed cotton rats stimulated
high titers of NA. Furthermore, VLP immunization of dams protected their offspring from
RSV challenge and decreased pathology in pups' lungs compared to pathology
observed after RSV infection of offspring of unimmunized dams. We also found that
maternal immunizations with VLPs containing different versions of the pre-fusion F
protein varied significantly in the extent of protection of offspring of vaccinated dams. We
identified one version of pre-fusion F VLPs that improved protection of offspring ten-fold
compared to the originally tested pre-F VLP.
It is our goal to move our VLP vaccine candidates toward clinical trials as a
maternal vaccine. To this end, we propose three specific tasks using cotton rats as
human surrogates.
Task 1: Develop protocols and processes for production and purification of cost
effective GMP VLP vaccine candidates on a large scale.
Task 2: Refine parameters of protection of neonates after maternal immunization.
Task 3: Assess and improve protective responses in mothers post-delivery.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Inducible HMGB1 antagonist for viral-induced acute lung injury.
-
批准号:10591804
-
项目类别:
-
资助金额:$48.81万
-
财政年份:2023
-
负责人:JORGE C BLANCO
-
依托单位:
RSV-induced M2 macrophage differentiation: role of TLR4/PPARg/RXR signaling axis (80)
-
批准号:10418803
-
项目类别:
-
资助金额:$19.01万
-
财政年份:2021
-
负责人:JORGE C BLANCO
-
依托单位:
RSV-induced M2 macrophage differentiation: role of TLR4/PPARg/RXR signaling axis (80)
-
批准号:10287155
-
项目类别:
-
资助金额:$24.17万
-
财政年份:2021
-
负责人:JORGE C BLANCO
-
依托单位:
Targeting TLR Signaling Pathways to Blunt Pathogen-mediated Acute Lung Injury
-
批准号:9306674
-
项目类别:
-
资助金额:$54.71万
-
财政年份:2017
-
负责人:JORGE C BLANCO
-
依托单位:
Targeting TLR Signaling Pathways to Blunt Pathogen-mediated Acute Lung Injury
-
批准号:10098763
-
项目类别:
-
资助金额:$5.22万
-
财政年份:2017
-
负责人:JORGE C BLANCO
-
依托单位:
Development of VLP vaccine for RSV
-
批准号:9137089
-
项目类别:
-
资助金额:$93.4万
-
财政年份:2014
-
负责人:JORGE C BLANCO
-
依托单位:
Development of VPL Vaccine for RSV
-
批准号:8645890
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2014
-
负责人:JORGE C BLANCO
-
依托单位:
Development of VLP vaccine for RSV
-
批准号:9334692
-
项目类别:
-
资助金额:$93.4万
-
财政年份:2014
-
负责人:JORGE C BLANCO
-
依托单位:
Eritoran (E5564), a TLR4 antagonist, as a novel therapeutic for influenza
-
批准号:8884533
-
项目类别:
-
资助金额:$86.55万
-
财政年份:2013
-
负责人:JORGE C BLANCO
-
依托单位:
Eritoran (E5564), a TLR4 antagonist, as a novel therapeutic for influenza
-
批准号:8711276
-
项目类别:
-
资助金额:$87.88万
-
财政年份:2013
-
负责人:JORGE C BLANCO
-
依托单位:
Eritoran (E5564), a TLR4 antagonist, as a novel therapeutic for influenza
-
批准号:9101944
-
项目类别:
-
资助金额:$86.55万
-
财政年份:2013
-
负责人:JORGE C BLANCO
-
依托单位:
Eritoran (E5564), a TLR4 antagonist, as a novel therapeutic for influenza
-
批准号:8473011
-
项目类别:
-
资助金额:$78.46万
-
财政年份:2013
-
负责人:JORGE C BLANCO
-
依托单位:
Development of the Cotton Rat Model of Rhinovirus Infection and Disease
-
批准号:8360839
-
项目类别:
-
资助金额:$27.48万
-
财政年份:2012
-
负责人:JORGE C BLANCO
-
依托单位:
Development of the Cotton Rat Model of Rhinovirus Infection and Disease
-
批准号:8486391
-
项目类别:
-
资助金额:$23.83万
-
财政年份:2012
-
负责人:JORGE C BLANCO
-
依托单位:
The role of TLR4 and RSV F protein in immunity to RSV
-
批准号:8254112
-
项目类别:
-
资助金额:$13.2万
-
财政年份:2010
-
负责人:JORGE C BLANCO
-
依托单位:
Treatment of RSV Bronchiolitis with NSAIDs
-
批准号:7106823
-
项目类别:
-
资助金额:$43.88万
-
财政年份:2006
-
负责人:JORGE C BLANCO
-
依托单位:
The role of TLR4 and RSV F protein in immunity to RSV
-
批准号:7730569
-
项目类别:
-
资助金额:$47.43万
-
财政年份:2004
-
负责人:JORGE C BLANCO
-
依托单位:
The role of TLR4 and RSV F protein in immunity to RSV
-
批准号:8473654
-
项目类别:
-
资助金额:$49.56万
-
财政年份:2004
-
负责人:JORGE C BLANCO
-
依托单位:
The Role of TLR4 and RSV F Protein in Immunity to RSV
-
批准号:7173903
-
项目类别:
-
资助金额:$49.07万
-
财政年份:2004
-
负责人:JORGE C BLANCO
-
依托单位:
The role of TLR4 and RSV F protein in immunity to RSV
-
批准号:8079543
-
项目类别:
-
资助金额:$53.27万
-
财政年份:2004
-
负责人:JORGE C BLANCO
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: